Yasmeen Rahimi, an analyst from Piper Sandler, has initiated a new Buy rating on Tenax Therapeutics (TENX).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yasmeen Rahimi’s rating is based on the promising potential of Tenax Therapeutics’ TNX-103, which is being developed for the treatment of Group 2 PH-HFpEF. The drug’s unique mechanism as a dual K+ ATP channel activator and calcium sensitizer offers a compelling therapeutic approach, addressing key aspects of the disease’s pathophysiology. The positive results from Phase 2 trials, including improvements in hemodynamics and exercise capacity, further bolster confidence in its efficacy and safety.
Moreover, the upcoming Phase 3 LEVEL trial, expected to provide results in the second half of 2026, is seen as a significant catalyst for the stock. The trial is designed with robust statistical power to detect meaningful improvements in the primary endpoint, which, if successful, could lead to regulatory approval in a market with high unmet needs. These factors contribute to the Buy rating, reflecting the potential for substantial future growth in Tenax Therapeutics’ stock value.